

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:31:21 +0000
To: Ms P
Subject: RE: A note from Sharon Perlman

Sharon:

Thanks for your note. It was great to hear from you. All is well with me and my family. I hope the same for you. This whole coronavirus situation is rather exhausting since I am working 24/7 with no breaks at all. However, it needs to be done since this virus is a true threat to global health.

Best regards,
Tony

From: Ms P [REDACTED] (b) (6)
Sent: Wednesday, February 26, 2020 6:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: A note from Sharon Perlman

Hi Dr. Fauci,

As I was watching my favorite CNN news show starring Chris Cuomo last night, to my delight, there you were! And again, this morning with John Berman and Alisyn Camerota on New Day.

I do hope all that all is well with you and your family. We are all doing fine. My

(b) (6)

I would love to hear from you, when you have time.

With best regards,
Sharon

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:27:18 +0000
To: Bennett Werner
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Clinical question, Sir....

Dear Drs. Werner and Uhl:

Thank you for your note.

(b) (6)

(b) (6)

Best regards,
A.S. Fauci

-----Original Message-----

From: Bennett Werner (b) (6) >
Sent: Wednesday, February 26, 2020 6:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Clinical question, Sir....

Dear Dr. Fauci,

(b) (6)

By the way, we both feel you are an outstanding spokesperson and really appreciate both the work you do and your clear explanations on Public TV (and elsewhere).

Warm regards,

Bennett E. Werner, M.D. FACC FACP
Cleveland Clinic Cardiology - (b) (6)

Michelle D. Uhl, M.D.
Cleveland Clinic - medical oncology (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:06:03 +0000
To: Morgan Fairchild
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Covid-19

Morgan:

Thanks for the note and the offer to help. It would be great if you could tweet to your many Twitter followers that although the current risk of coronavirus to the American public is low, the fact that there is community spread of virus in a number of countries besides China and including South Korea, Japan, Italy, Iran among others poses a risk that we may progress to a global pandemic of COVID-19. If that occurs we will surely have many more cases in the USA. And so for that reason, the American public should not be frightened, but should be prepared to mitigate an outbreak in this country by measures that include social distancing, teleworking, temporary closure of schools, etc. There is nothing to be done right now since there are so few cases in this country and these cases are being properly isolated, and so go about your daily business. However, be aware that behavioral adjustments may need to be made if a pandemic occurs.

Best regards,
Tony

From: Morgan Fairchild (b) (6)
Sent: Wednesday, February 26, 2020 8:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Covid-19

Hi Dr. Fauci. I'm reaching out to see if I can help in any way to get good information out to the public, as I tried to do with AIDS. I have almost 100,000 Twitter followers and have been tweeting articles to them that I feel are helpful, but if you have any info I can help disseminate, please let me know.

Also, a great job today and this week!!

Hope you're well!

Thanks!

Best,

Morgan

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 03:00:14 +0000
To: Laura Landerman-Garber
Subject: RE: Dr Sheldon Wolff Dr Fauci NIH [REDACTED] (b) (6)
Follow up 2/26/20

Laura:

Many thanks for your kind note. It was great to hear from you.
Warm regards,
Tony

From: Laura Landerman-Garber [REDACTED] (b) (6) >
Sent: Wednesday, February 26, 2020 9:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [REDACTED] (b) (6) >
Subject: Re: Dr Sheldon Wolff Dr Fauci NIH [REDACTED] (b) (6) Follow up 2/26/20

Greetings from New Hampshire. Today I was watching the news and there you were, once again popping up in my life and making me not only smile by your kind and approachable style that I truly remember from the [REDACTED] (b) (6), but also taken care of by your expertise. Thank you for your medical leadership during these days as the Coronavirus spreads. Please know that your legacy of research and practice will live on for generations to come!
I hope that these complex days are soon quieted for us here in the US and around the Globe

Ps [REDACTED] (b) (6).
Amazing to think that so many of my questions were answered all those decades ago with you and Sheldon Wolff I remain forever grateful. Since I saw you last, [REDACTED] (b) (6) who you met, moved to DC and works at American Psychological Association. [REDACTED] (b) (6). Life marches on. I hope you and your family are well

Best,

Laura Landerman-Garber, Ph.D.

On Apr 7, 2015, at 12:18 PM, Fauci, Anthony (NIH/NIAID) [E]
[REDACTED] (b) (6) wrote:

Laura:

Thank you so much for your beautiful note. I do remember you and am so happy that you reached out to communicate with me. I am very pleased to hear that you are doing so well. You have "made my day" by your note. I wish you and your family all the best.

Warm regards,
Tony

From: Laura Landerman-Garber (b) (6)
Sent: Tuesday, April 07, 2015 10:31 AM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Dr Sheldon Wolff Dr Fauci NIH (b) (6) Follow up


See below please. Thank you!!

Sent from my iPhone

Begin forwarded message:

From: Laura Landerman (b) (6)
Date: April 7, 2015 at 10:06:28 AM EDT
To: "niaidnews@niaid.nih.gov" <niaidnews@niaid.nih.gov>
Subject: Dr Anthony Fauci/ NIH/ Dr SHeldon Wolff/ (b) (6)
followup
Reply-To: Laura Landerman (b) (6) >

Greetings from NH. I am trying to contact Dr Fauci after many years. I have followed his career like so many others do... (b) (6)
(b) (6)



I am not sure if this can find its way to Dr Fauci but I would so appreciate it if it could. To let him know that all those years ago,

he left n outstanding impression on [REDACTED] (b) (6)
[REDACTED]. I want to thank him from the bottom of my heart.

Sincerely,

Laura M. Landerman-Garber, Ph.D.

[REDACTED] (b) (6)

[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 02:57:57 +0000
To: LOUIS FORTUNATO
Subject: RE: Dear Tony: Will you take the lead in the Coronavirus problem/ we always love you/Saw you on CNN/

Lou:

I do not believe that there is a chance to republish Harrison Practice.
Best regards,
Tony

From: LOUIS FORTUNATO [REDACTED] (b) (6)
Sent: Wednesday, February 26, 2020 9:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Fwd: Dear Tony: Will you take the lead in the Coronavirus problem/ we always love you/Saw you on CNN/

Begin forwarded message:

From: LOUIS FORTUNATO [REDACTED] (b) (6) >
Subject: Fwd: Any Chance of Harrison Practice being updated and replaced on the market? I loved it Tony/ Better than Harrison's Textbook
Date: February 17, 2020 at 9:41:40 PM EST
To: [REDACTED] (b) (6)

Dear Tony Fauci MD:
Any chance for Harrison Practice being republished again and updated with the newest Pathophysiology and Treatments?
It was better than Harrisons Textbook/More Precise and Succinct

Please email me/
I would greatly appreciate your response
either wayYes or No//

Dr Lou Fortunato
[REDACTED] (b) (6)

Begin forwarded message:

From: LOUIS FORTUNATO [REDACTED] (b) (6) >
Subject: HERE TONY IS ANOTHER CHAPTER OF MY FUTURE NUC MED BOOK
Date: November 3, 2019 at 5:11:19 AM EST
To: [REDACTED] (b) (6)

HERE TONY IS MY NOTES IN BONE
IMAGING FOR MY FUTURE BOOK

LOU FORTUNATO

From: (b) (6)
Sent: Wed, 26 Feb 2020 20:24:59 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: [EXTERNAL] Gene-RADAR platform for Real time Mobile (POC) Coronavirus detection/ viral load monitoring/ Followup to our meeting at the ASPEN ideas festival -

Please handle.

Sent from my iPhone

Begin forwarded message:

From: "Dr. Anita Goel , M.D., Ph.D." (b) (6)>
Date: February 26, 2020 at 7:58:54 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: FW: [EXTERNAL] Gene-RADAR platform for Real time Mobile (POC) Coronavirus detection/ viral load monitoring/ Followup to our meeting at the ASPEN ideas festival -

Dear Dr. Anthony Fauci,

It was a great pleasure meeting you all a couple of years ago when we were both speaking at the Aspen Ideas Festival. Some of my contacts at the CDC recently briefed me about the rapidly emerging threat of the coronavirus to the US and have been urging us to develop an app for detecting coronavirus with high sensitivity and specificity on our Gene-RADAR platform. Our platform has the ability to quantify viral loads in 'real-time' which would be a much more precise and accurate solution in deciding quarantine than the current thermometers or even the current CDC coronavirus test which has a very poor Limit of detection (ie low sensitivity).

We have a strong track record of responding to previous pandemic threats and rapidly building Gene RADAR applications for Ebola and Zika and then getting them through clinical validation as per the the FDA EUA approval process. Our Gene-RADAR Zika test was FDA EUA certified right as the Zika crisis was coming to an end.

I would love to work with you to see how we can help in your efforts to rapidly respond to this deadly threat to the US and the world. Here are some of the capabilities of our platform that we believe could be an enabler for helping to stop this outbreak from becoming a full-fledged global pandemic.

- Gene-RADAR platform for Real time Mobile (POC) Coronavirus detection/ viral load monitoring
 - Highly sensitive and specific – minimize false positives and false negatives
 - With very good LOD's we could potentially start to catch people presymptomatically and enable the early detection , early quarantine would limit the spread and early intervention could lead to better outcomes
 - More precise viral load monitoring could help determine when to release people from quarantine or ICU beds
 - Our platform's ability to quantify vial loads could change clinical trial endpoints for new drug candidates or (repurposed drug formulations), thereby accelerating FDA approvals for novel therapeutic regimen
 - We already have an ISO 13485 certified manufacturing facility (currently in Boston) that we are prepared to move as fast as possible to ramp up our production

We would love to work with you to repurpose our FDA approved platform for the above coronavirus applications assay and help your noble efforts to stop this outbreak from becoming a full blown global pandemic that could costs thousands of lives and cause trillions of dollars of economic damage to the global economy.

We would love to speak with you to brief on our capabilities and discuss how we can qualify for some of the emergency funding being made available to help tackle this pandemic threat.

Happy to jump on a phone call to discuss further how we can help

How Nanobiophysics can Stop Ebola and Other Global Pandemics

- [Forbes](#)
- [Wired Magazine](#)

Best Wishes,

Dr. Anita Goel, MD, PhD
Chairman &CEO
Nanobiosym

=====
www.nanobiosym.com
 email: (b) (6)
 Mobile: (b) (6)
<http://www.people.fas.harvard.edu/~goel/>
 email: goel@physics.harvard.edu
 =====

Selected Media Links:

[Nanobiosym Gene-RADAR® X Prize Grand Prize Winner Video](#)

[Dr. Goel's Article in Scientific American Worldview](#)
[Nanobiosym Chairman &CEO Named 2018 Uber ELITE Award Winner](#)
[FDA Grants Emergency Use Authorization for Gene-RADAR® Zika Test](#)
[BBC Feature: The Genius Behind the "Tricorder that could revolutionize medicine"](#)
[Nanobiosym Selected As One Of The Top Growth Stage Ventures By The 'Unreasonable' Group](#)
[Dr. Anita Goel, MD, PhD awarded 2019 SEEMA Entrepreneur of the Year Award](#)

How Nanobiophysics can Stop Ebola and Other Global Pandemics

- [Forbes](#)
- [Wired Magazine](#)

[Nanobiosym Global Initiative Summit Website](#)

[Wall Street Journal](#)
[Washington Post](#)
[Boston Globe GameChangers](#)
[National Geographic](#)
[Forbes](#)

Nanobiosym Space News

[CBS News](#)
[Boston Business Journal](#)
[CNN](#)
[DailyMail](#)
[Space.com](#)
[Popular Mechanics](#)
[Forbes](#)
[US News and World Report](#)
[Wired](#)
[Daily Press](#)
[CBC Radio](#)
[Boston Globe STAT](#)

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

From: (b) (6)
Sent: Wed, 26 Feb 2020 19:24:48 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Interview request from WTOP [Please reply all]

Sent from my iPhone

Begin forwarded message:

From: "Anderson, Liz" <landerson@wtop.com>
Date: February 26, 2020 at 6:57:05 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Cc: "Spitalniak, Laura" <lspitalniak@wtop.com>
Subject: Interview request from WTOP [Please reply all]

Good Evening Dr. Fauci,

My name is Liz Anderson, and I'm working the editor's desk tonight at WTOP.

Are you available for a brief live interview (about 2 minutes long) about what the latest COVID-19 developments? During this evening's press conference, President Trump said you two spoke about it.

The Washington Post is also reporting that the CDC has been informed about the first coronavirus case of unknown origin confirmed in Northern California. We'd also like to talk about that and what that could mean about the spread of this virus in the states.

We have the following time slots open tonight:

9:10p

9:40p

10:10p

10:40p

11:10p

11:40p

Many thanks for your time.

Sincerely,

Liz Anderson

AE/Editor/Reporter, WTOP News

202-895-5060 (newsroom)

landerson@wtop.com

Twitter: @planetnoun

<http://wtop.com/author/landerson/>

<http://wtop.com/author/liz-anderson/>

wtop | 103.5 FM
WTOP.COM

From: (b) (6)
Sent: Wed, 26 Feb 2020 19:24:09 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Interview request from WTOP [Please reply all]

Sent from my iPhone

Begin forwarded message:

From: "Anderson, Liz" <landerson@wtop.com>
Date: February 26, 2020 at 7:01:22 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Subject: RE: Interview request from WTOP [Please reply all]

Wait-- I see you're at the press conference, too. If you have availability at one of the times listed, we'd love to have you.

Many thanks,

Liz

From: Anderson, Liz
Sent: Wednesday, February 26, 2020 6:57 PM
To: (b) (6) >
Cc: Spitalniak, Laura <lspitalniak@wtop.com>
Subject: Interview request from WTOP [Please reply all]

Good Evening Dr. Fauci,

My name is Liz Anderson, and I'm working the editor's desk tonight at WTOP.

Are you available for a brief live interview (about 2 minutes long) about what the latest COVID-19 developments? During this evening's press conference, President Trump said you two spoke about it.

The Washington Post is also reporting that the CDC has been informed about the first coronavirus case of unknown origin confirmed in Northern California. We'd also like to talk about that and what that could mean about the spread of this virus in the states.

We have the following time slots open tonight:

9:10p

9:40p

10:10p

10:40p

11:10p

11:40p

Many thanks for your time.

Sincerely,

Liz Anderson

AE/Editor/Reporter, WTOP News

202-895-5060 (newsroom)

landerson@wtop.com

Twitter: @planetnoun

<http://wtop.com/author/landerson/>

<http://wtop.com/author/liz-anderson/>

wtop | 103.5 FM
WTOP.COM

From: (b) (6)
Sent: Wed, 26 Feb 2020 19:22:28 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: AM 970 the Answer Radio Request Re: Coronavirus Response from POTUS and NIH

Sent from my iPhone

Begin forwarded message:

From: Alex Garrett <agarrett@nycradio.com>
Date: February 26, 2020 at 7:13:41 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: AM 970 the Answer Radio Request Re: Coronavirus Response from POTUS and NIH

Hi Dr. Fauci,

I hope you are well ! Would love to welcome you to Kevin McCullough Radio on AM 970 the Answer tomorrow to discuss the steps the White House and the NIH are taking to combat coronavirus. Kevin is our drive-time host at 5 PM and he is nationally syndicated as well with 300+ affiliates for his broadcast!

Look forward to hearing from you. Thanks Dr. Fauci!

Alex Garrett

Producer: Kevin McCullough Radio
AM 570 the Mission WMCA: 3-4 PM
AM 970 the Answer: 5-6 PM

From: Folkers, Greg (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 21:50:05 +0000
To: Laurencot, Elizabeth;Fauci, Anthony (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E]
Subject: RE: NEJM content proof (Fauci)

Eli,

(b) (5)

Thanks,
Tony

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Wednesday, February 26, 2020 4:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Eisinger, Robert (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6) Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Subject: RE: NEJM content proof (Fauci)

Dear Dr Fauci,

Regarding the following information--

(b) (5)

Please clarify --- thank you!

Best,
Eli

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) > **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]

Sent: Wednesday, February 26, 2020 3:48 PM

To: Laurencot, Elizabeth <elaurencot@nejm.org>; Fauci, Anthony (NIH/NIAID) [E]

(b) (6) >


Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Eisinger, Robert (NIH/NIAID) [E]

(b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID)

[E] (b) (6)

Subject: RE: NEJM content proof (Fauci)

Dear Eli,



Thanks,
Tony

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Wednesday, February 26, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Dr Fauci,

Many thanks for your quick reply and for the clear list of responses regarding the proof. I will review today and will let you know if there are any items needing further discussion.

The current plan is for publication early Friday afternoon. As I mentioned yesterday, there is a new article on Covid-19 that is also scheduled for publication that day, and the Journal editors would like you to mention it in your editorial. I expect to be able to send you a proof of that article sometime today.


Best,
Eli


From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 26, 2020 7:37 AM
To: Laurencot, Elizabeth <elaurencot@nejm.org>
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Eli,

Here are my answers to your queries, and couple other minor changes:

(b) (5)





Thanks,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Tuesday, February 25, 2020 8:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: NEJM content proof (Fauci)
Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read *ALL* of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurençot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (<http://www.adobe.com/products/acrobat/readermain.html>).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended

recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: (b) (6)
Sent: Wed, 26 Feb 2020 15:29:21 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Re: Seeking Dr. Fauci for coronavirus webinar

Let us discuss

On Feb 26, 2020, at 11:59 AM, Conrad, Patricia (NIH/NIAID) [E]
(b) (6) wrote:

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Chris Adams <cadams@nationalpress.org>
Sent: Wednesday, February 26, 2020 11:01 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Seeking Dr. Fauci for coronavirus webinar

Patricia:

I hope you are doing well. Dr. Fauci has been a wonderful speaker for us in the past, and I'm reaching out to him today for a discussion on coronavirus.

When there are major news stories, we often will try to do a live webinar on the topic with a leading expert or two.

This is something we would do in our studio at our office near Dupont Circle. We normally do them for 45-60 minutes, and we take questions (via Twitter) from our audience. The audience would be reporters who cover the topic, as well as others interested in the topic. It is a way to have an in-depth, thoughtful conversation about a pressing topic.

Here are a couple we've done (the first is on Zika a few years ago):

Zika panel discussion: <https://nationalpress.org/topic/understanding-the-zika-threat/?st=0&t=&mm=Video>

Ted Koppel: <https://nationalpress.org/toolbox-topic/lights-out-risks-to-the-power-grid/?st=7042&mm=Video>

Autonomous vehicles panel discussion: <https://nationalpress.org/topic/whats-new-with-autonomous-vehicles/?st=8474&t=Automation&mm=Story>

We'd like to do one of these on coronavirus. We'd love to have Dr. Fauci as our prime guest.

We can schedule it around his demands, but would of course love to do it as soon as possible.

We know he is in demand at this moment. But he is such a singular expert on the topic we'd love to have a discussion with him – one that would help get his message out to journalists (and others) who need to be informed to best cover the topic.

Is it possible to check with Dr. Fauci to see if this is possible?

Thanks,
Chris Adams
National Press Foundation

From: (b) (6)
Sent: Wed, 26 Feb 2020 15:01:39 -0500
To: Folkers, Greg (NIH/NIAID) [E]
Cc: Eisinger, Robert (NIH/NIAID) [E]
Subject: Re: ASF and CLIFF ----- DRAFT response to Eli at NEJM

Please send this to Eli. Thanks

On Feb 26, 2020, at 12:49 PM, Folkers, Greg (NIH/NIAID) [E]
(b) (6) wrote:

Dear Eli,

(b) (5)



From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Wednesday, February 26, 2020 11:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Eisinger, Robert (NIH/NIAID) [E] <(b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: RE: NEJM content proof (Fauci)
Importance: High

Dear Dr Fauci,



Thank you very much for your consideration!

Best,
Eli

From: Laurencot, Elizabeth
Sent: Wednesday, February 26, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Eisinger, Robert (NIH/NIAID) [E] (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Dr Fauci,

Many thanks for your quick reply and for the clear list of responses regarding the proof. I will review today and will let you know if there are any items needing further discussion.

The current plan is for publication early Friday afternoon. As I mentioned yesterday, there is a new article on Covid-19 that is also scheduled for publication that day, and the Journal editors would like you to mention it in your editorial. I expect to be able to send you a proof of that article sometime today.


Best,
Eli

From: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Sent: Wednesday, February 26, 2020 7:37 AM
To: Laurencot, Elizabeth <elaurencot@nejm.org>
Cc: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6); Eisinger, Robert (NIH/NIAID) [E] [REDACTED] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6); Lane, Cliff (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Eli,

Here are my answers to your queries, and couple other minor changes:





Thanks,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>

Sent: Tuesday, February 25, 2020 8:51 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: NEJM content proof (Fauci)

Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read *ALL* of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurençot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (<http://www.adobe.com/products/acrobat/readermain.html>).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

<NEJMoa2002032_Guan_Content2_Author.pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 17:33:08 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Subject: RE: remarks for White House press conference
Attachments: Fauci remarks Feb 26 - with minor edit.docx

I have made a minor tweak.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6) >
Sent: Wednesday, February 26, 2020 12:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Stover, Kathy (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6) >
Subject: remarks for White House press conference

Dr. Fauci,

Attached for review are proposed remarks (in bullet format) for the White House press conference.

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C

Bethesda, MD 20892

Direct: [REDACTED] (b) (6)

[REDACTED] (b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 16:49:43 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: BBC Radio

What say you?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Paul Coletti <paul.coletti@bbc.co.uk>
Sent: Wednesday, February 26, 2020 11:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: BBC Radio

Dear Dr. Fauci,

Newshour on the BBC World Service is today covering the US preparedness on the Coronavirus

Would you be available for interview on this topic?

We're on air at 3pm eastern and could speak to you live at around 3:10pm or alternatively we could record a few minutes between now and then. About 8 minutes duration and we've many ways to connect to get good audio (no video as we are radio).

If there is interest from your side then I'm on + (b) (6)

Yours sincerely,

Paul Coletti
Tel: (b) (6)
Twitter: @bbeworldservice, @pcoletti
Newshour podcasts: www.bbc.co.uk/podcasts/series/newshour

BBC World Service listen live: www.bbc.co.uk/worldserviceradio/on-air

Newshour is the award-winning news and current affairs programme on BBC World Service English, the radio and online network which reaches 75 million listeners each week, including 12.5 million in the USA on National Public Radio.

Paul Coletti

Tel: [REDACTED] (b) (6)

Twitter: @bbeworldservice, @pcoletti

Newshour podcasts: www.bbc.co.uk/podcasts/series/newshour

BBC World Service listen live: www.bbc.co.uk/worldserviceradio/on-air

Newshour is the award-winning news and current affairs programme on BBC World Service English, the radio and online network which reaches 75 million listeners each week, including 12.5 million in the USA on National Public Radio.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 16:37:50 +0000
To: Johnson, Martin S. (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Appropriators going to have a call at 3:30 in Larry's office with HHS Op divs on the COVID-19 Supplemental Request

Martin:

You and Hugh should be on the call.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Johnson, Martin S. (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 26, 2020 11:17 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Appropriators going to have a call at 3:30 in Larry's office with HHS Op divs on the COVID-19 Supplemental Request

Tony,

Appropriators going to have a call at 3:30 in Larry's office with HHS Op Divs concerning the 2020 supplemental request.

Larry wants someone from NIAID to also be on the call. Please advise who you want to attend.

Thanks

Martin

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 16:36:36 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: SIBF inquiry

Please say no to this. Too busy.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Shannon Williams <shannon.williams@sibf.org>
Sent: Wednesday, February 26, 2020 11:10 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: SIBF inquiry
Importance: High

Dear Dr. Fauci,

I am writing to inquire about your willingness to address the Society of International Business Fellows (SIBF) as part of our webinar series. SIBF is a distinguished organization of nearly 1600 global executives and senior leaders. Our C-level global membership would appreciate getting your perspectives on the coronavirus outbreak. We are open to topics which could include....What we know and don't know...As business and community leaders what SIBF members can do to prepare and educate their employees...Safety of travel, etc.

We were thinking the webinar could be approximately 30 minutes in length (15 minutes of remarks followed by 15 minutes of Q&A). SIBF's Communications Manager could work with someone on your team to set-up the webinar. SIBF is a

non-profit, but we are able to provide a \$2k honorarium to you or a charity of your choice.

Thank you for your gracious consideration and attention to our request. It is our sincere hope that you will be able to participate.

Best regards,

Mr. Shannon George Williams | Director of Programs
Society of International Business Fellows (SIBF)
715 Peachtree Street NE, Suite 200
Atlanta, GA 30308
P: (470) 378-1151 W: www.sibf.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 16:27:37 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: MSNBC Guest Request 2/26

FYI. Please handle as you see fit.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hirsch, Nancy (NBCUniversal) <Nancy.Hirsch@nbcuni.com>
Sent: Wednesday, February 26, 2020 10:59 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: MSNBC Guest Request 2/26

Hello Dr. Fauci

I hope this finds you well and I am sure receiving numerous requests

Would you be avail to join anchor Ari Melber tonight 6 pm EST to speak to Trumps presser and the latest on Coronavirus?

Thank you for letting me know if you can join soonest possible.

Nancy

Nancy Hirsch

The Beat with Ari Melber
Mavericks with Ari Melber
Booking Producer

30 Rockefeller Plaza | New York, NY 10112

(T) 212-664-4097

(C) [REDACTED] (b) (6)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:22:01 +0000
To: Eisinger, Robert (NIH/NIAID) [E]; Greg Folkers ([REDACTED] (b) (6))
Subject: FW: NEJM content proof (Fauci)

See below. I will need your help on this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: ([REDACTED] (b) (6))
FAX: (301) 496-4409
E-mail: ([REDACTED] (b) (6))

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Wednesday, February 26, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] ([REDACTED] (b) (6))
Cc: Folkers, Greg (NIH/NIAID) [E] ([REDACTED] (b) (6)); Conrad, Patricia (NIH/NIAID) [E] ([REDACTED] (b) (6)); Eisinger, Robert (NIH/NIAID) [E] ([REDACTED] (b) (6)); Lane, Cliff (NIH/NIAID) [E] ([REDACTED] (b) (6))
Subject: RE: NEJM content proof (Fauci)

Dear Dr Fauci,

Many thanks for your quick reply and for the clear list of responses regarding the proof. I will review today and will let you know if there are any items needing further discussion.

The current plan is for publication early Friday afternoon. As I mentioned yesterday, there is a new article on Covid-19 that is also scheduled for publication that day, and the Journal editors would like you to mention it in your editorial. I expect to be able to send you a proof of that article sometime today.

Best,
Eli

From: Fauci, Anthony (NIH/NIAID) [E] ([REDACTED] (b) (6))
Sent: Wednesday, February 26, 2020 7:37 AM
To: Laurencot, Elizabeth <elaurencot@nejm.org>

Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] < (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)>
Subject: RE: NEJM content proof (Fauci)

Dear Eli,

Here are my answers to your queries, and couple other minor changes:

(b) (5)



Thanks,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>

Sent: Tuesday, February 25, 2020 8:51 AM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Subject: NEJM content proof (Fauci)

Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read *ALL* of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurençot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (<http://www.adobe.com/products/acrobat/readermain.html>).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:18:06 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: First in class, hemostatic drug - potential therapeutics for COVID-19
Attachments: NIAID EEEV - SP16_ Jan 28, 2020 - Read-Only - Read-Only.pdf, JACC manuscript Oct 2017 SP16 AMI (1).pdf, Serpin Pharma - Non-Confidential Partnering Deck v29.pdf

Please take a look at this. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cohava Gelber (b) (6)
Sent: Tuesday, February 25, 2020 8:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: First in class, hemostatic drug - potential therapeutics for COVID-19
Importance: High

Dear Dr. Fauci,

(b) (4)



Please let us know how we can help.

I have attached a manuscript and company presentations for your review.

Sincerely,

Cohava

Cohava Gelber, PhD, MBA
Executive Chairperson & CEO
Serpina Pharma
www.serpina.com

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:17:35 +0000
To: Mehta, Nehal N. (NIH/NHLBI) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Greg Folkers [REDACTED] (b) (6)
Subject: RE: Guidance for users of biologics in the age of Coronavirus.

I am sorry Nehal, but I am really swamped right now and cannot make this a priority. I hope that you understand.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mehta, Nehal N. (NIH/NHLBI) [E] [REDACTED] (b) (6) >
Sent: Tuesday, February 25, 2020 8:47 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Fwd: Guidance for users of biologics in the age of Coronavirus.

Dear Tony-

I wonder if you would be willing to participate in a short piece regarding use of biologics with looming Coronavirus for JAMA Dermatology or JAMA Internal Medicine?

Please see the email sent below to me by my colleague and collaborator Joel Gelfand from Penn.

I understand there are fierce demands on your time but we would be happy to draft for your approval.

Many thanks for your consideration!

All my best,
Nehal

Nehal N. Mehta, MD MSCE FAHA

Lasker Senior Investigator

Chief, Lab of Inflammation and Cardiometabolic Diseases

National Heart, Lung and Blood Institute

Bethesda MD 20892

Email [REDACTED] (b) (6)

Phone: [REDACTED] (b) (6)

Begin forwarded message:

From: "Gelfand, Joel" [REDACTED] (b) (6)

Date: February 25, 2020 at 8:12:48 PM EST

To: "Mehta, Nehal N. (NIH/NHLBI) [E]" [REDACTED] (b) (6)

Subject: Guidance for users of biologics in the age of Coronavirus.

Dear Nehal,

With the coronavirus bordering on a pandemic and the expectation that it will affect the US at some point, it seems to me we should be prepared to provide guidance to patients who are on immune modulators for inflammatory disease. Specifically, many will wonder if patients should stop their biologic if the virus becomes prevalent in their community. There will also be questions about stopping biologics in the setting of acute infection with coronavirus.

Any thoughts on this? My specific interests relates to patients with psoriasis or psoriatic arthritis on biologics but it's also relevant to patients with IBD, RA and other inflammatory diseases.

Joel

Joel M. Gelfand MD, MSCE

Professor of Dermatology

Professor of Epidemiology

Vice Chair for Clinical Research (Dermatology)

University of Pennsylvania, Perelman School of Medicine

<https://www.med.upenn.edu/gelfand/>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:14:43 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft MA re: Fauci/Eisinger/Redfield COVID-19 paper

This looks fine. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, February 25, 2020 5:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: FOR ASF REVIEW: Draft MA re: Fauci/Eisinger/Redfield COVID-19 paper

Hi Dr. Fauci,

Please find attached for your review a draft media availability about your imminent NEJM paper on COVID-19. We have named you as the spokesperson in the MA.

Thanks much,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A17F

Bethesda, MD 20892

(b) (6)

Media line: (301) 402-1663

From: (b) (6)
Sent: Wed, 26 Feb 2020 09:23:22 -0500
To: Thomas R. Frieden
Subject: Re: FYI

Thanks, Tom.

On Feb 25, 2020, at 3:41 PM, Thomas R. Frieden
<(b) (6)> wrote:

Tony,

Nothing you don't already know....

Tom

From: Tom Frieden (b) (6)>
Date: Tuesday, February 25, 2020 at 3:39 PM
To: Tom Frieden (b) (6)
Subject: A COVID-19 Pandemic is Inevitable. Now what?

Dear Colleague,

It's now clear that COVID-19 will become a pandemic. We don't know if it will be mild, moderate or severe, or how many countries it will reach.

As we shift from the initiation phase of the pandemic to the acceleration stage, I've highlighted 8 things we must do now in a new CNN OpEd:

<http://www.cnn.com/2020/02/25/health/coronavirus-pandemic-frieden/index.html>

Please share, and thank you for what you continue to do for public health.

All the best,

Tom

If you'd like to retweet, here's a [link](#).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 12:47:09 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: Milken outreach

Thanks, Francis. It might be better for you to make an e-mail introduction and I will take it from there.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Wednesday, February 26, 2020 7:32 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: RE: Milken outreach

He's at (b) (6) and (b) (6) Want to reach out directly or shall I make an e-mail introduction?

Francis

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 26, 2020 6:43 AM
To: Collins, Francis (NIH/OD) [E] (b) (6)
Subject: Re: Milken outreach

Francis:

Thanks for the note. Milken can help in a number of ways including directly supporting the VRC. Also, as we start looking for Pharma to step up with us, his connections could be helpful.

Tony

On Feb 25, 2020, at 12:58 PM, Collins, Francis (NIH/OD) [E] (b) (6) > wrote:

Hi Tony,

I'm sure you know Michael Milken. I've worked with him over many years, and though he is a somewhat controversial figure he has certainly helped NIH in many ways. He reached out to me last night to ask if there is anything he could do to help with the coronavirus vaccine effort. He had seen press reports that finding a pharma partner had been challenging – and wanted to volunteer his help in that regard, since he has deep connections in the private sector. He also said that he'd be glad to help with any philanthropic needs, both through his own resources and his influence over members of the Giving Pledge.

Are there useful actions that I can suggest to him?

FC

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 10:59:30 +0000
To: 辛恩波
Subject: RE: Questions about the coronavirus—Chinese Media Inquiry:

See answers below in **red**

From: 辛恩波 <xinenbo@thepaper.cn>
Sent: Wednesday, February 26, 2020 1:08 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Questions about the coronavirus—Chinese Media Inquiry:

Dear Dr Fauci,

My Name is Paul Xin, I'm a journalist from Pengpai News(ThePaper) of Shanghai, which is one of the most important new media in China. I'm Sorry to bother you as you must be very busy. I noticed your comment about coronavirus on American media, I deeply hope you could answer few of my questions. Your answers will be very helpful to me. The questions are below.

Thank you very much!

Sincerely,
Paul Xin

1/You said on CNN that US have had pandemic preparedness plan that developed in preparation for pandemic influenza. Could you provide some details of this plan? **The plan outlines the differences between containment and mitigation. It speaks of the thing that should be done if an outbreak occurs in the USA. These include social distancing, use of telecommunication and telework, temporarily closing schools, avoiding crowded places such as indoor arenas and theaters.**

2/To prepare for potential communities spread of coronavirus in US, do you think that US need take the measures similar with China? **China was in the "reactive" mode of responding to an explosion of cases in Wuhan City and Hubei province with spread throughout China. China had to resort to very dramatic measures such as shutting down cities. The USA is now in a preparative mode and not a reactive mode and so our response is much different than that of China.**



辛恩波

澎湃新闻/时事新闻中心/国际新闻部

上海市延安中路839号

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 10:46:23 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Confirmation from CNN's New Day

Got it. Thanks.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 26, 2020 5:40 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Fwd: Confirmation from CNN's New Day

Firm for 650 am hit today at med arts as per below.

Sent from my iPhone

Begin forwarded message:

From: "Figliola, Mike" <Mike.Figliola@turner.com>
Date: February 26, 2020 at 3:33:40 AM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)>, "Daniels, Ronnel (NIH/OD/ORS) [C]" (b) (6)>, "Ryland, Ken (NIH/OD/ORS) [E]" (b) (6)>, Jonathan Bennett (b) (6), "Jackson Farrar, Joy (NIH/OD/ORS) [E]" (b) (6)
Subject: RE: Confirmation from CNN's New Day

Hi everyone,
This is Mike with CNN's New Day. Hope you are well.
This is to confirm Dr. Fauci will be a guest today, **Wednesday 02.26.20** at around **6:50am EST** to discuss:

6E:

Coronavirus latest – are we facing an outbreak?

You will be **solo at 6:45am EST** for the segments.

John Berman, will both be conducting today's interview.

Please arrive at the studio no later than **6:40am EST**.

Here is your studio confirmation:

SHOW MANAGER: VENDOR STUDIO #2018562
NIH Events Management (Medical Arts) Studio Info
NIH Control Room numbers are 301-827-8478 and 8479
Encompass Booking and Circuit Number:
Booking: 1-800-243-1995
Circuit: 36TBGS104492
Our IFB: 301-496-1811 (we prefer to call into the station's IFB)
Video: 1080i (59.94) - the audio is embedded.
Please call the TOC with any technical questions at 301-827-8478

Please confirm you have received this and are all set to go!

Best,

M

Mike Figliola
Editorial Producer
CNN's New Day
212-275-8161
mike.figliola@turner.com



CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 01:32:22 +0000
To: Jon LaPook
Subject: RE: CBS Sunday Morning

Jon:

The message would have to be that the situation continues to evolve and people need to follow the news and the reports from CDC. For example, a few weeks ago if you wanted to travel to Japan or South Korea, it was fine since there were few if any cases there. Now both countries have a travel alert that says "Avoid all but essential travel". You should tell people that travel to places with few or no reported cases is fine. Only when you have community spread (person to person to person) should you be concerned about a specific travel destination. Also, you could explain to people that pandemics evolve when a new infectious disease is spreading by sustained community spread in multiple countries in different regions of the globe. Once a pandemic erupts, it is virtually impossible for any country to be free of cases. People need to understand that. You can mitigate the effects, but you cannot avoid having infections since you cannot shut off the country from the rest of the world. Also, you need to speak of the real and present danger of seasonal influenza every year. Do not let the fear of the unknown (i.e. a pandemic of a new infectious agent) distort your evaluation of the risk of the pandemic to you relative to the risks that you face every day. The only thing that we can do is to prepare as best as possible and do not yield to unreasonable fear.

Best,
Tony

-----Original Message-----

From: Jon LaPook <(b) (6)>
Sent: Tuesday, February 25, 2020 6:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: CBS Sunday Morning

Hi Tony,

I have an unusual opportunity: the executive producer of CBS Sunday Morning has asked me to do a straight to camera shpiel about COVID-19 for this Sunday. I did something similar when people are panicking about Ebola.

You and I have spoken enough about this so that I feel comfortable with the basics. But I would love you to give some thought to whether there are any misunderstandings that you would like cleared up or information you would like disseminated.

I would love to give some logical travel advice. I know there are so many unknowns, but I have had multiple people ask me whether they should cancel their upcoming trip to ... you name it (Italy, Israel, San Francisco). I know it comes down to risk/benefit, and - as you told me during the Ebola outbreak - people have all sorts of varying levels of comfort with risk. But what do I actually SAY to the 6 million people who will be watching people? :)

Thanks,
Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: (b) (6)
Sent: Tue, 25 Feb 2020 19:07:15 -0500
To: McNeil Jr, Donald G
Subject: Re: thought from a kibbitzer...

You make some very good points, Donald.

On Feb 25, 2020, at 4:48 PM, McNeil Jr, Donald G <meneil@nytimes.com>wrote:

I was just watching the HHS briefing online, and thinking about an article I read this morning, and Bruce Aylward's description of what he saw in China, and a lot of [videos I've watched](#) on the South China Morning Post website (they're doing great coverage.).

In China, we in the media tend to report the horrors and the lockdown and the government's early lies...

But the truth is that a lot of average Chinese behaved incredibly heroically in the face of the virus: 25,000 doctors and nurses went into Wuhan to help, knowing they might die. Average people gave up their stockpiles of masks so they could be shipped to Wuhan. Neighborhood committees brought food to thousands of little old ladies and checked on them every day, even as they asked them to stay behind their doors for fear of infection.

Meanwhile, in America, people tend to act like selfish pigs interested only in saving themselves. How can I hoard a mask? Where's my vaccine? This morning, I read [this appalling article](#) from Alabama. Here you have Americans coming back from a horrifying experience overseas, and the President -- who is popular in Alabama -- asks Alabamans to take some of those fellow Americans in. There is zero risk because they're going to be housed on a naval base.

And yet, the answer is "No! Keep them out!" And their legislators encourage it....

I dunno -- that's the kind of behavior I expect from my fellow New Yorkers, not from Alabama.

If the virus arrives -- and we both know it will -- America is going to have to do better than that. Like the Chinese, Americans are going to have to look out for each other the way we haven't since 9/11. Or maybe since World War II.

But that's not the tone of the HHS briefings. They're an aggressive, defensive, almost smart-alecky "we got this" tone. The only time the tone was right when you

were the third to take the mike and explain things to that kid shouting from the back without a mike about "What's the real message? What do we do?"

Maybe there could be some thought given to mentally preparing Americans to work together in the face of the crisis? Quarantines are a very aggressive approach -- but they require a lot of compassion or the people quarantined suffer.

I might get around to writing an article about this, but my editors keep grabbing me for minute by minute stuff and I'm way behind.

Donald

From: (b) (6)
Sent: Tue, 25 Feb 2020 18:59:02 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Surfactant Protein-D against coronavirus

Please handle.

Begin forwarded message:

From: Marc Salzberg <(b) (6)>
Date: February 25, 2020 at 4:42:47 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: Surfactant Protein-D against coronavirus

Dear Dr. Fauci,

We are developing a recombinant human form of Surfactant Protein-D (AT-100), an endogenous collectin with strong immune-modulatory properties. AT-100 shows anti-inflammatory and anti-infectious properties. (b) (4)

(b) (4) There are data indicating that SP-D clears coronavirus (<https://www.ncbi.nlm.nih.gov/pubmed/19439011>). (b) (4)

While we are discussing this with a number of academic institutions, I was wondering, though, whether you and the NIH are interested to collaborate on evaluating AT-100 against coronavirus. Please let me know, if you are willing to schedule a phone call with our Chief Medical Officer Dr. Paul Kingma and I to discuss. There is obviously a sense of urgency behind this request.

Best regards,

Marc Salzberg

Airway Therapeutics, Inc.
Marc Salzberg, MD
President & CEO
1200 Johnson Ferry Rd., Suite 300
Marietta, GA 30068

Ph

(b) (6)



From: (b) (6)
Sent: Tue, 25 Feb 2020 18:33:00 -0500
To: David - Gmail
Subject: Re: David Pyrce Reconnecting - Coronavirus Task Force

David:

Thanks for your note and your keen interest in this important challenge of coronavirus. The White House Task Force is chosen by the President upon the advice of his senior staff. I am afraid that there will not be any additional members for now. Again, thank you for your interest. Best regards,

Tony

On Feb 25, 2020, at 5:29 PM, David - (b) (6) wrote:

Hello Dr. Fauci,

I know you are extremely busy and will get right to the point. I would like to join the coronavirus taskforce.

I worked on the Ebola task force about six years ago, which had a similar sense of urgency, and recognize that assembling a SWAT team overnight is critically important in order to monitor, contain and mitigate the spread of the coronavirus, not just for the United States, but on a worldwide basis.

I've done a significant amount of work in infectious disease vaccine development at a number of biotech firms (Vical, Inovio and Intrexon) in partnership with the NIH, Vaccine Research Center, DOD and the CDC.

I also (b) (6) we discuss preparedness on a daily basis. Those conversations clearly indicate that the knowledge and expertise is severely lacking at both the academic medical center level, as well as the community health level.

I believe my assistance can be deployed in several areas where my experience in virology, immunology, antivirals, Ebola, product development and strategic partnering could be of immediate value to research scientists, medical professionals and healthcare systems.

1. Identification of emerging therapeutics.
2. Fast track emerging therapeutics from pre-clinical to IND and fast-track clinical trials.
3. Identify opportunities to accelerate the production of commercial quantities of therapeutic material.
4. Identify unique genomic fingerprints of responders and patients undergoing treatment to guide therapeutic selection and optimize interventions.
5. Interface with public and/or institutional stakeholders on a worldwide basis (24/7) regarding safety procedures, diagnostics, therapeutic interventions, etc.
6. Other initiatives, representing areas where there is an immediate need to bring on board and deploy an individual with deep expertise, who can provide leadership, drop in and rapidly advance those initiatives.

With the urgency required, in order to provide a Navy SEAL like response, I would propose a consulting arrangement where I'm available 24/7, anywhere/anytime, for as long as needed. Please let me know your thoughts.

Here is a brief snapshot of my C.V.

1. SVP, Innovation and Chief Commercial Officer – NantKwest (gene/cell therapies, immunotherapeutics and molecular diagnostics)
2. SVP, Innovation and Chief Commercial Officer – NantHealth (AI/bioinformatics-based multi-omics based molecular diagnostics and neoantigen-based therapeutics)
3. Founder/CEO - Genomic Principles (neoantigen-based, individualized therapeutic vaccines)
4. Founder/CEO Canton Biotechnologies (DNA-based therapeutics and vaccines)
5. Chief Business Officer – Intrexon (gene/protein-based therapeutics and vaccines)
6. Chief Business Officer - Inovio (gene-based therapeutics and vaccines)
7. VP, Business Development – Vical (gene-based therapeutics and vaccines).

I know you are busy and you can feel free to forward this email to the appropriate individual. I can also be reached by cell phone [REDACTED] (b) (6) to discuss further.

Best Wishes,

David

David Pyrcce

Cel [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 22:10:15 +0000
To: NIAID OD AM
Subject: FW: Hello from [REDACTED] (b) (6)

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Groslyn Burton <burton@theasiagroup.com>
Sent: Tuesday, February 25, 2020 10:59 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Hello from [REDACTED] (b) (6)

Dr. Fauci -

I hope this note finds you well. [REDACTED] (b) (6)

[REDACTED] I apologize for the direct out of the blue message, however, my company The Asia Group has a podcast called Tea Leaves and we would be interested in having you as a guest to speak about the Coronavirus. I mentioned to my CEO that you are the leading expert and that I had a connection with you. We would only take about 30-45 mins of your time and would be happy to work around your schedule if this is something that you would be willing to do. Below is a short description of the podcast and a link to our episodes. If able, I'd be happy to coordinate with your assistant.

Looking forward to hearing back soon.

Thanks,
Groslyn "Foster" Burton
Vice President, Culture and Values
Executive Assistant to the Chairman
Dr. Kurt M. Campbell, Chairman and CEO
The Asia Group, LLC

202-350-3285 – Office

(b) (6) – Mobile

202-750-2944 – Fax

The Asia Group announced the launch of Tea Leaves, a new podcast that will focus on the current affairs, foreign policy, business, and arts of Asia. The podcasts' hosts, Dr. Kurt M. Campbell and Ambassador Richard Verma, will lead a series of revealing interviews with policymakers, business leaders, journalists, and artists exploring the most dynamic and consequential region in the world.

In a joint statement, Campbell and Verma said, "We wanted to share our passion for Asia with listeners, both accomplished Asia hands and those with a budding interest in the dynamic region. Our aim is to provide listeners with a greater understanding of the individuals who focus on and live in the region, and how Asia affects our world."

The hosts bring significant experience and expertise to the podcast. Campbell is CEO and Chairman of The Asia Group, and served as Assistant Secretary of State for East Asian & Pacific Affairs from 2009 to 2013. Richard Verma is Vice Chairman and Partner at The Asia Group, and served as the United States Ambassador to India from 2015 to 2017.

The first episode of Tea Leaves is now live on major podcast platforms, including iTunes, Stitcher, and Overcast. Subsequent episodes will be animated by conversations with the movers, doers, and thinkers who are driving today's Indo-Pacific. "We hope that you will subscribe and give our first episode a listen," said Campbell and Verma.

The link to the podcast is available here: <https://itunes.apple.com/us/podcast/the-tea-leaves-podcast/id1355207045>

From: (b) (6)
Sent: Tue, 25 Feb 2020 16:08:53 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: The Last Word with Lawrence O'Donnell

Let us discuss

Begin forwarded message:

From: "Shuster, Amy (NBCUniversal, MSNBC)" <amy.shuster@msnbc.com>
Date: February 25, 2020 at 3:40:25 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6), "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: The Last Word with Lawrence O'Donnell

Good afternoon,

I wonder if Dr. Fauci could join our program this evening at 10 pm to discuss the best measures for the government and the American people to prepare for a coronavirus pandemic.

Ali Velshi is hosting our show tonight on MSNBC.

This would be a panel discussion this evening – we're still working through details of the panel.

Interview would be from 10-10:20 pm EST.

Please let me know if anything would be possible tonight.

Many thanks,
Amy

Amy Shuster
Senior Producer
The Last Word
o. 212-664-1657
c. (b) (6)

From: (b) (6)
Sent: Tue, 25 Feb 2020 14:03:48 -0500
To: Ziady, Hanna (NE)
Subject: Re: Questions on coronavirus vaccine

45 people. It will take 3 to 4 months to complete.

On Feb 25, 2020, at 11:12 AM, Ziady, Hanna (NE)
<Hanna.Ziady@turner.com>wrote:

Thanks very much for the quick response.

Do you know at this stage when the phase 1 trial will be completed and how many people will participate in it?

Many thanks,
Hanna

Hanna Ziady
Writer | CNN Business
O: +44 207 693 1884
M: + (b) (6)
@hannaziady

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Date: Tuesday, 25 February 2020 at 15:58
To: "Ziady, Hanna (NE)" <Hanna.Ziady@turner.com>
Subject: RE: Questions on coronavirus vaccine

The phase 1 trial to determine safety for the mRNA vaccine platform that NIH is doing with Moderna is scheduled to start within 2 months (some time in April). However, this is just the first step in attempting to have a vaccine available for use. Even proceeding at an emergency speed, a vaccine would not be available for use for at least 1 to 1.5 years. It is characterized as a "vaccine".

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ziady, Hanna (NE) <Hanna.Ziady@turner.com>

Sent: Tuesday, February 25, 2020 5:56 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >

Subject: Questions on coronavirus vaccine

Dear Dr Fauci,

Trust this mail finds you well.

I have a few questions regarding the Moderna vaccine, which it would be great to get your input on.

Is it true that trials of the possible vaccine will start in April, but that, even if the first study is positive, the vaccine might not become widely available until next year because of the need for further studies and regulatory clearances?

The company is characterizing this as a vaccine. Strictly speaking, what should it be referred to as?

If you have time for a quick telephone call this morning as soon as you're able that would be great.

Many thanks,
Hanna

Hanna Ziady
Writer, CNN Business
Office: +44 207 693 1884
Mobile: (b) (6)
@hannaziady

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please

notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

From: (b) (6)
Sent: Tue, 25 Feb 2020 13:56:38 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Re: cdc coronavirus

This does not change anything I said this AM. It is perfectly compatible with what I said. No conflict at all.

On Feb 25, 2020, at 1:32 PM, Conrad, Patricia (NIH/NIAID) [E]
(b) (6) >wrote:

Pls advise

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jakaitis, Mike <mjakaitis@wtop.com>
Sent: Tuesday, February 25, 2020 1:26 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: cdc coronavirus

The CDC today alerted Americans to begin to prepare for community spread of the coronavirus.....does this changes Dr. Fauci's view on the virus? If so can he join us. If this doesn't change anything. We can use what he said this morning....or if he wants to come on and talk about the new CDC warning...we would like to speak to him.

From: (b) (6)
Sent: Tue, 25 Feb 2020 13:52:31 -0500
To: James Rae
Subject: Re: touch screens transmitting Coronavirus

Mr. Rae:

Thank you for your note.
Best regards,
A.S. Fauci

> On Feb 25, 2020, at 1:36 PM, James Rae (b) (6) > wrote:

>

> Dear Dr. Fauci-

>

> Thanks for your tv appearances to educate.

>

> Cell phone and other touch screens could be a major vector of transmission for Coronavirus.

>

> Please suggest frequent cleaning of devices with alcohol on your next tv appearance.

>

> Keep up the good work. I've watched you over the years. Your public education is much appreciated.

>

> Best regards,

>

> Jim Rae

> Boston area

> (b) (6) mobile

From: (b) (6)
Sent: Tue, 25 Feb 2020 13:09:02 -0500
To: Emanuel, Ezekiel J
Cc: (b) (6)
Subject: Re:

It may well diminish somewhat as weather gets warmer. However, there is no guarantee that this will occur. More likely that it will become seasonal and go down in our summer and resurge next winter

On Feb 25, 2020, at 12:48 PM, Emanuel, Ezekiel J (b) (6) >wrote:

To get 1 million deaths of 1957 would require 200 million infections at a death rate of 0.5%. That seems high number of infections.

But what is the worldwide seasonal flu death numbers if the USA has 50,000 deaths in a bad year and the 1957 number of deaths was 116,000? The WHO says 650,000 deaths worldwide from seasonal flu. So this could be worse but by about 40% not an order of magnitude. Okay so I should be more concerned.

And do you think it will go down in late spring with warmer weather?

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost for Global Initiatives
Diane v.S. Levy and Robert M. Levy University Professor
Chair, Department of Medical Ethics and Health Policy ((b) (6))
Co-Director, Healthcare Transformation Institute
University of Pennsylvania

Phone: (b) (6)
Fax: 215-898-6567

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, February 25, 2020 12:32 PM
To: Emanuel, Ezekiel J < (b) (6) >
Subject: RE:

Zeke:

Ari is also calling me frequently. The virus has adapted itself very well to humans with considerable community transmission (certainly in China) now in other countries such as South Korea, Japan, Iran, Italy, etc. If it continues to spread via multiple generations of human to human transmission, then we will not be able to avoid considerable amounts of infections and spread in the USA. Seasonal influenza has a mortality of 0.1%. The calculated mortality of COVID-19 to about 2.5 %. It is probably lower since the denominator is likely larger than we appreciate due to asymptomatic infections. Even if the mortality goes down to 0.5%, that is still equivalent to a pandemic influenza of 1957 or 1968. In other words, it could be worse than you think.

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Emanuel, Ezekiel J (b) (6)
Sent: Tuesday, February 25, 2020 10:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject:

Tony,

Ari is pestering me endlessly. What is your latest update and assessment on coronavirus? I still am having a hard time seeing this as serious as everyone else. Am I blind? Yes very transmissible but low mortality like flu in many ways—the elderly, those with comorbidities, and total impact is likely to be less than flu. Also travel restrictions are delaying but not stopping virus.

Am I missing something big or small?

Thanks

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost for Global Initiatives

Diane v.S. Levy and Robert M. Levy University Professor

Chair, Department of Medical Ethics and Health Policy ([REDACTED] (b) (6)
[REDACTED])

Co-Director, Healthcare Transformation Institute

University of Pennsylvania

Phone: [REDACTED] (b) (6)

Fax: 215-898-6567

From: (b) (6)
Sent: Tue, 25 Feb 2020 13:04:40 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: DDP4 Inhibitors and ACE2 Inhibitors :: Spike Protein Binding in MERS and SARS

Please handle. Thanks

Begin forwarded message:

From: Joel Meyer (b) (6) >
Date: February 25, 2020 at 12:32:24 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: DDP4 Inhibitors and ACE2 Inhibitors :: Spike Protein Binding in MERS and SARS

Dear Dr. Fauci,
Is it possible that DDP4 and ACE2 inhibitors would be effective in preventing coronavirus entry and thereby 'de-rail' the infectious cycle?
Thank you for your work and guidance to NIAID!
Sincerely,
Joel R.L. Meyer

(b) (6)
(b) (6)

=====
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891363/>

"Coronavirus entry is initiated by the binding of the spike protein (S) to cell receptors, specifically, dipeptidyl peptidase 4 (DDP4) and angiotensin converting enzyme 2 (ACE2) for MERS-CoV and SARS-CoV, respectively [1-5]"

...

References

1. Masters, PS., Perlman, S. Coronaviridae in Field's Virology. Knipe, DM., Howley, PM., editors. Vol. 1. Lippincott, Williams &Wilkins; Philadelphia: 2013. p. 825-858.
2. Coleman CM, Frieman MB. Coronaviruses: important emerging human pathogens. J Virol. 2014; 88:5209-5212. [PubMed: 24600003]
3. De Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nature Rev Microbiol. 2016; 14:523-534. [PubMed: 27344959]

4. Greenberg SB. Update on human rhinovirus and coronavirus infections. *Sem Respir Crit Care Med.* 2016; 37:555–571.
5. Vijay R, Perlman S. Middle East respiratory syndrome and severe acute respiratory syndrome. *Curr Opin Virol.* 2016; 16:70–76. [PubMed: 26855039]

From: (b) (6)
Sent: Tue, 25 Feb 2020 13:02:20 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Doctor Radio followup special

Please see if this is possible. Thanks

Begin forwarded message:

From: "Siegel, Marc" <Marc.Siegel@nyulangone.org>
Date: February 25, 2020 at 12:07:19 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Cc: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>, Beth Ameen
<beth.ameen@siriusxm.com>
Subject: Doctor Radio followup special

Hi Tony

Am wondering if you might have a few minutes to join us by phone again this
Friday between
3 and 4 on coronavirus
Would mean alot.
Marc

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 17:25:40 +0000
To: Gary Simon
Cc: Graham, Barney (NIH/VRC) [E]; Ledgerwood, Julie (NIH/NIAID) [E]; 'Chen, Grace (NIH/NIAID) [E]'; Conrad, Patricia (NIH/NIAID) [E]; Mascola, John (NIH/VRC) [E]
Subject: RE: Coronavirus vaccine

Thanks, Garry. I will pass your note on to the people who will be conducting the phase 1 vaccine trial here at NIH.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gary Simon (b) (6) >
Sent: Tuesday, February 25, 2020 10:42 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus vaccine

Dear Tony,

I'm not sure which email you use. (b) (4)

It would certainly expedite getting samples to NIH for immune assays.

gary

Gary L. Simon, MD, PhD, MACP
Walter G. Ross Professor of Medicine

Director, Division of Infectious Diseases
Vice-Chairman, Department of Medicine
T (b) (6)
F 202 741-2241

Confidentiality Note: This e-mail is intended only for the person or entity to which it is addressed and may contain information that is privileged, confidential or otherwise protected from disclosure. Dissemination, distribution or copying of this e-mail or the information herein by anyone other than the intended recipient, or an employee or agent responsible for delivering the message to the intended recipient, is prohibited. If you have received this e-mail in error, please call (202) 741-3636 and destroy the original message and all copies.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 17:15:43 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Collaboration proposal on [REDACTED] (b) (4)
variants
Attachments: Macrogen (Dr. Jeong-sun Seo) letter to Dr. Anthony Fauci.pdf

Please handle and respond to this person. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ogan Gurel, MD [REDACTED] (b) (6) >
Sent: Tuesday, February 25, 2020 9:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Jeongsun Seo MD PhD [REDACTED] (b) (6); Changhoon Kim PhD [REDACTED] (b) (6); Moon-Young Shin [REDACTED] (b) (6)
Subject: Collaboration proposal on [REDACTED] (b) (4)

Dear Dr. Fauci,

Greetings and thank you for all your outstanding scientific and policy leadership regarding the evolving Covid-19 situation.

I am writing to you from South Korea where, as you well know, we are experiencing a very difficult phase of the epidemic. Among the several groups I have been engaged with to address this crisis, I am working with the genome sequencing company, Macrogen, which you may already be familiar with (<https://dna.macrogen.com/eng/>). Dr. Jeongsun Seo, the Chairman of Macrogen, along with other company leaders and myself have been discussing [REDACTED] (b) (4)

(b) (4)

(b) (4)

Barring the institution of any extreme travel restrictions, I am planning to visit the Bethesda area next week (Macrogen U.S. HQ is located in Rockville). I know you are extraordinarily busy but if you (or key colleagues) have time, I and other senior Macrogen colleagues would be happy to discuss the project, its necessary next steps, along with any other matters related to Korea as you wish. [Please note that I do not have any clinical symptoms or signs of Covid-19 nor any relevant contact history.]

Thank you very much for your attention to this matter and I hope that we may have a chance to advance this important project together.

Please take care and thanks again,

Ogan

(b) (6)

 <http://www.linkedin.com/in/ogangurel>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 17:08:19 +0000
To: Eisinger, Robert (NIH/NIAID) [E]; Greg Folkers [REDACTED] (b) (6)
Subject: FW: NEJM content proof (Fauci)
Attachments: NEJMe2002387_Fauci_Content2_Author.pdf

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Tuesday, February 25, 2020 8:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: NEJM content proof (Fauci)
Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read *ALL* of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurençot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (<http://www.adobe.com/products/acrobat/readmain.html>).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 17:07:30 +0000
To: Eisinger, Robert (NIH/NIAID) [E]; Greg Folkers (b) (6)
Subject: FW: NEJM content proof (Fauci)
Attachments: NEJMe2002387_Fauci_Content2_Author.pdf

Please take a look at this for me and proof to the extent that you can. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Tuesday, February 25, 2020 8:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: NEJM content proof (Fauci)
Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read *ALL* of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurençot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (<http://www.adobe.com/products/acrobat/readmain.html>).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 15:55:19 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: The global health leaders call, Wednesday 26 February at 13:00 CET
Attachments: (b) (4) Swisscom Call code.pdf

Please print out for tomorrow AM.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: RYAN, Michael J. (b) (6)
Sent: Tuesday, February 25, 2020 4:10 AM
To: Redfield, Robert R. (CDC/OD) (b) (6)
(b) (6)
David Heymann (b) (6); Felicity Harvey
(b) (6) Chris.Elias
(b) (6); Jeremy Farrar
(b) (6) Fauci, Anthony
(NIH/NIAID) [E] (b) (6)
Conrad, Patricia (NIH/NIAID) [E]
(b) (6) Thomas R. Frieden (b) (6)
>; Lynn Banks (b) (6); President | Resolve to Save Lives
<president@resolvetosavelives.org> (b) (6)
(b) (6)
(b) (6)
Tarik Mohammed (b) (6)
Cc: SHOC <shoc@who.int>; Office of the Director-General <DGOoffice@who.int>; SCHWARTLANDER, Bernhard F. (b) (6); MAHJOUR, Jaouad (b) (6); FALL, Ibrahima Soce (b) (6); GREIN, Thomas <(b) (6)>; MINHAS, Raman (b) (6); COX, Paul Michael (b) (6); AL-SHORBAJI, Farah (b) (6); POOLE, Marcia (b) (6); DRURY, Patrick Anthony (b) (6); GRAAFF, Peter Jan (b) (6); Dr VAN KERKHOVE, Maria (b) (6); KABIR, Sophia

(b) (6)

Subject: The global health leaders call, Wednesday 26 February at 13:00 CET

Dear colleagues,

Dr Tedros would like to invite you to the next informal discussion about the ongoing 2019 novel coronavirus.

The teleconference will be hosted tomorrow Wednesday, 26 February at 13:00 CET and the dial-in number with a passcode is attached.

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: +41227912490

It would be appreciated if you could kindly confirm your participation to Ms Sophia Kabir, email:

(b) (6) ; mobile no. (b) (6)

Best,

Mike

From: [REDACTED] (b) (6)
Sent: Tue, 25 Feb 2020 07:30:31 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Bloomberg Radio 2/25

Let us discuss

Begin forwarded message:

From: "Jameelah D Robinson (BLOOMBERG/ NEWSROOM:)"
<jrobinson158@bloomberg.net>
Date: February 25, 2020 at 7:25:43 AM EST
To: "NIAID NEWS (NIH/NIAID)" <NIAIDNEWS@niaid.nih.gov>
Cc: "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6)
Subject: Bloomberg Radio 2/25
Reply-To: "Jameelah D Robinson" <jrobinson158@bloomberg.net>

Hi Dr. Fauci!

I Hope this email finds you well. I'm emailing to see if you can join Tom Keene, Bloomberg Suveillance Anchor/Editor-at-Large on his radio show tomorrow morning as a PHONER at 8:15am Et to discuss the Coronavirus. Please let me know if we can make this happen. Many thanks!

-Jameelah

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 03:27:11 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: NIAF and coronavirus

Let us discuss.

From: Elvis Oxley <eoxley@bdo.com>
Sent: Monday, February 24, 2020 9:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Eric Jia-Sobota <esobota@bdo.com>
Subject: NIAF and coronavirus

Dr. Fauci, I trust this email finds you well. It has been a few years since we've seen one another on the Hill or at a NIAF event but hopefully we will rectify that soon.

I know you have a lot on your plate, especially with the coronavirus, but I am curious if you have five minutes for a call tomorrow so I can introduce you to my boss at BDO, Eric Jia-Soboda (<https://www.linkedin.com/in/eric-jia-sobota-02156036/>). Eric is an expert in cost accounting for Life Sciences companies and he wants to glean your perspective on the likely structure of the emergency coronavirus budget request so that NIH and others can maximize those research and implementation dollars at the most rapid pace. We would certainly appreciate your time.

My best, Elvis

Elvis Oxley
Managing Director
Industry Specialty Services
(b) (6) (Mobile)
703-245-8665 (Direct)
eoxley@bdo.com

BDO
Greater Washington D.C.
8401 Greensboro Drive, Suite 800
McLean, VA 22102
www.bdo.com

BDO USA, LLP, a Delaware limited liability partnership, is the U.S. member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms.

BDO is the brand name for the BDO network and for each of the BDO Member Firms.

IMPORTANT NOTICES

The contents of this email and any attachments to it may contain privileged and confidential information from

BDO USA, LLP. This information is only for the viewing or use of the intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of, or the taking of any action in reliance upon, the information contained in this e-mail, or any of the attachments to this e-mail, is strictly prohibited and that this e-mail and all of the attachments to this e-mail, if any, must be immediately returned to BDO USA, LLP or destroyed and, in either case, this e-mail and all attachments to this e-mail must be immediately deleted from your computer without making any copies hereof. If you have received this e-mail in error, please notify BDO USA, LLP by e-mail immediately.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 03:26:06 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Subject: RE: Close of Day Note for 2/24/2020 re: coronavirus preparedness

No, I did not see this. You should tell Jim Gillman to copy me on everything that relates to this issue since I am the one who will be dealing with the Congress, the President and the press about all of this.

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)
Sent: Monday, February 24, 2020 9:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: FW: Close of Day Note for 2/24/2020 re: coronavirus preparedness

Tony,
I assume you have already seen this, but just in case....
Larry

From: "Gilman, James (NIH/CC/OD) [E]" (b) (6) >
Date: Monday, February 24, 2020 at 5:50 PM
To: "Tabak, Lawrence (NIH/OD) [E]" (b) (6) >, Francis Collins
(b) (6), "Gottesman, Michael (NIH/OD) [E]" (b) (6) >
Subject: Close of Day Note for 2/24/2020 re: coronavirus preparedness

Francis / Larry / Michael:



(b) (5)

Jim

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 23:38:09 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: LA Magazine / Interview request

Let us discuss.

From: jmcgahan [REDACTED] (b) (6)
Sent: Monday, February 24, 2020 6:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: LA Magazine / Interview request

Dear Dr. Fauci,

You and I haven't met. I'm a long-time writer for Los Angeles Magazine. We're doing a cover story for the April issue on the threat of the new coronavirus poses to the 10 million inhabitants of metropolitan Los Angeles. Would you be available for an interview on Wednesday?

Thanks,
Jason

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 22:42:57 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Welcome packet & consent form | The Coronavirus Outbreak: Tracking COVID-19 | Forum
Attachments: 3.2.20 Consent form .pdf, 3.2.20 Forum welcome document.pdf, 3.2.20 Green room agenda .pdf

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dweck, Kristen <kdweck@hsph.harvard.edu>
Sent: Monday, February 24, 2020 5:34 PM
To: (b) (6) Lipsitch, Marc (b) (6)
Yip, Winnie Chi-Man (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: (b) (6) Osborn, Elizabeth (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Subject: Welcome packet & consent form | The Coronavirus Outbreak: Tracking COVID-19 | Forum
Importance: High

Good evening,

Please find attached, The Forum welcome document, green room agenda and consent form. The welcome packet includes information about our production along with what to wear while on camera. The Harvard T.H. Chan School of Public Health consent form is required for production of webcast series.

Please sign and scan a copy of the consent form back by **March 2, 2020.**

We look forward to an exciting event!

Best,
Kristen Dweck

--

Kristen A. Dweck

Digital Media and Engagement Manager, The Leadership Studio
Harvard T.H. Chan School of Public Health
677 Huntington Avenue, Kresge 329 | Boston, MA 02115
o: 617-432-1268 | f: 617-432-1780
kdweck@hsph.harvard.edu



Join the conversation:

[The Forum](#) | [Twitter](#) | [YouTube](#) | [iPhone and iPad](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 22:34:05 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Re:Following up on NIH visit

What is this?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>
Sent: Monday, February 24, 2020 4:04 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Hoffman, Hillary (NIH/NIAID) [E] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Segre, Julie (NIH/NHGRI) [E] (b) (6)
Subject: RE: Re:Following up on NIH visit

Dear Hillary,
Thanks for your email.
I am indeed looking forward to my NIH visit on Friday, and am still hoping I might get some time with Dr. Fauci, though I can appreciate he might be busier than either of us expected to be back when we first scheduled my interview with him!
Warm regards,
Jason

Jason Gale, MHlthSec
Senior editor | Bloomberg News
Level 30, 120 Collins St., Melbourne VIC 3000

Tel. (landline) +61-3-9228-8783 | Mobile (b) (6)
@jwgale | LinkedIn: <http://www.linkedin.com/pub/jason-gale/6/249/a56>

From: (b) (6) At: 02/25/20 06:47:17
To: Jason Gale (BLOOMBERG/ NEWSROOM:)
Subject: RE: Re:Following up on NIH visit

Hi Jason,

Hope you have/had safe travels to DC this week! I wanted to check in to confirm that you're still planning on coming to visit us at NIH this Friday?

Currently, Dr. Myles is holding 10am and Dr. Belkaid is holding 1:30pm to discuss their microbiome-related research with you. Dr. Fauci's schedule has been very fluid lately due to the coronavirus outbreak—we'll likely need to check in with his assistant Patty Conrad on Thursday to see how his Friday calendar looks (unless you hear otherwise from Patty directly).

Best,
Hillary

Hillary Hoffman, Ph.D., Writer/Editor
Office of Communications and Government Relations, NIAID, NIH
5601 Fishers Lane #6G38
Rockville, MD 20852

(b) (6)

(b) (6)

From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>
Sent: Tuesday, January 28, 2020 4:39 PM
To: Hoffman, Hillary (NIH/NIAID) [E] (b) (6)>
Subject: RE: Re:Following up on NIH visit

Sounds good. Many thanks.

----- Original Message -----

From: Hillary Hoffman (b) (6)>
To: JASON GALE
At: 29-Jan-2020 08:38:46

Sounds good – I'll ask Dr. Myles to hold 10am, so you can chat with him before you meet Dr. Fauci at 11. We can re-confirm timing closer to the date. I'll tag along, and can make sure you get where you need to – you'll get to visit several different buildings, fortunately all close by!

From: Jason Gale (BLOOMBERG/ NEWSROOM:)
<j.gale@bloomberg.net>
Sent: Tuesday, January 28, 2020 4:32 PM
To: Hoffman, Hillary (NIH/NIAID) [E] <[REDACTED]> (b) (6)>
Subject: RE: Re:Following up on NIH visit

Hi Hillary
Late night for me on 2019-nCoV...
Shall we say before DrFauci? Then I'll know better how to get to him. 😊
Thanks a lot. Jason

----- Original Message -----
From: Hillary Hoffman [REDACTED] (b) (6)
To: JASON GALE
CC: [REDACTED] (b) (6)
At: 29-Jan-2020 06:34:55

Hi Jason,

Great speaking with you last week. I wanted to follow up to let you know that Yasmine Belkaid and Ian Myles—whose work we discussed on host-microbe interactions and developing a bacteria-based treatment for eczema, respectively—are willing to meet with you on Feb. 28.

Here are links to some background info:

- Dr. Belkaid's [lab page](#), and recent [NIAID press release](#) about a skin microbiome study from her lab
- Dr. Myles' [lab page](#), and [NIAID press release about findings from a Ph 1/2 trial](#) assessing the *R. mucosa* treatment for eczema

Dr. Belkaid is available at 1:30pm (her building is next to the Clinical Center, where you'll be meeting with Julie Segre I believe from 12-1ish). Dr. Myles' schedule is a bit more flexible, and he's currently available to meet either in the morning before you speak with Dr. Fauci or later in the afternoon after Dr. Belkaid (Dr. Myles is in the Clinical Center, about a 5 min walk from Dr. Fauci's building) – let me know if you have a timing preference. We can firm up times a bit closer to the date, but wanted to give you an update.

Best,
Hillary

Hillary Hoffman, Ph.D., Writer/Editor
Office of Communications and Government Relations, NIAID,
NIH
5601 Fishers Lane #6G38
Rockville, MD 20852

(b) (6)

(b) (6)

From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>
Sent: Thursday, January 23, 2020 4:09 PM
To: Hoffman, Hillary (NIH/NIAID) [E] <hillary.hoffman@nih.gov>
Cc: Routh, Jennifer (NIH/NIAID) [E] <jennifer.routh@nih.gov>
Subject: RE: Re:Following up on NIH visit

Sorry!! Getting on now

From: (b) (6) At:
01/24/20 08:07:48
To: Jason Gale (BLOOMBERG/ NEWSROOM:)
Cc: (b) (6)
Subject: RE: Re:Following up on NIH
visit

Hi Jason,

Wanted to check that you're still able to join us this afternoon/morning -- and that you aren't having issues calling into the conference line. Jen and I are both on.

Thanks, and hope to talk soon!
Hillary

From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>
Sent: Friday, January 17, 2020 3:02 PM
To: Hoffman, Hillary (NIH/NIAID) [E] <(b) (6)>
Cc: Routh, Jennifer (NIH/NIAID) [E]

(b) (6) >

Subject: RE: Re:Following up on NIH visit

Awesome. Thanks a lot.

----- Original Message -----

From: Hillary Hoffman

(b) (6)

To: JASON GALE

CC: (b) (6)

At: 18-Jan-2020 01:31:40

Hi Jason,

Yes, 4pm next Thursday (8am Friday for you) works for us. I will send out a calendar invitation with call-in information later today.

Enjoy your time off, and looking forward to speaking with you next week!

Best,
Hillary

From: Jason Gale
(BLOOMBERG/
NEWSROOM:)
<j.gale@bloomberg.net>

Sent: Thursday, January 16, 2020 6:24 PM

To: Hoffman, Hillary
(NIH/NIAID) [E]

<(b) (6)>

Cc: Routh, Jennifer
(NIH/NIAID) [E]

(b) (6) >

Subject: RE: Re:Following up on NIH visit

Dear Hillary,
Thanks for your email.
I am on vacation Mon-

Thursday next week.
Would a 4 pm call on
Thursday Jan. 23 (8 am
Friday for me) work?
I just saw happened to
see this report, FYI:
<https://medicalxpress.com/news/2020-01-gut-bacteria-parkinson.html?fbclid=IwAR2OXNzDroX9zaHhP73A22pK2zOP2cRQ6YJjdQo-icbKrNkrjoPrQ9Z0>

It's a good example of
the growing awareness
that the Human
Microbiome Project is
helping to provide of
the complex
interactions with
various biological
processes that underpin
health and disease.
Have a great weekend,
jason

From:
[REDACTED] (b) (6)
At: 01/17/20 03:22:49
To: [Jason Gale](#)
([BLOOMBERG/ NEWSROOM:](#))
Cc:
[REDACTED] (b) (6)
Subject: RE:
Re:Following up on NIH
visit

Hi Jason,

Great to hear of
your interest in
microbiome and flu
research. Jen and I
would be happy to
chat about what
NIAID may be able

to offer in terms of
subject matter
experts and
storylines in those
areas.

Might you be
available for a short
call next week
between 4-5pm
EST on either
Tues., Wed., or
Thurs. afternoon –
corresponding to 8-
9am Melbourne
time on Wed.,
Thurs., or Fri.
morning (assuming
I've got my time
zones correct)? If
we can't find a
mutually convenient
time, happy to
continue
discussions over
email.

Best,
Hillary

Hillary Hoffman, Ph.D.,
Writer/Editor
Office of
Communications and
Government Relations,
NIAID, NIH

(b) (6)

Media line: 301-402-
1663

From: Jason Gale
(BLOOMBERG/
NEWSROOM:)
<j.gale@bloomberg.net>
Sent: Wednesday,

January 15, 2020
11:56 PM

To: Rancourt, Anne
(NIH/NIAID) [E]

[REDACTED] (b) (6)

Cc: Leifman, Laura
(NIH/NIAID) [E]

[REDACTED] (b) (6)

Hoffman,
Hillary (NIH/NIAID)

[E]

[REDACTED] (b) (6)

; Routh,
Jennifer

(NIH/NIAID) [E]

[REDACTED] (b) (6)

Lavelle,
Judith (NIH/NIAID)

[E]

[REDACTED] (b) (6)

Segre, Julie
(NIH/NHGRI) [E]

[REDACTED] (b) (6)

Subject: RE:
Re:Following up on
NIH visit

Hi Anne,
Thanks a lot
for your email
and your
suggestions!
After my last
visit to NIH
(and meeting
with Lisa
Proctor and
Julie Segre
years ago), we
did the
attached story
on the gut
microbiome.
We're very
keen to look

at doing a
podcast series
on the
microbiome
(skin, gut,
other
anatomical
bits) and how
it's informing
our views on
health,
disease and
the way we
prevent and
treat
diseases.

It would be
cool to
workshop this
theme with you
and your
colleagues
before my
visit, if you
have some
time?

I cut my teeth
in medical
science
writing on
(bird) flu and
would be
interested in
the research
Jeffrey
Taubenberger's
lab is doing,
but my
understanding
(and I could
be wrong) is
that there's
still a lot of
work to be
done in
producing a
universal flu

shot. If such
vaccine
candidates are
still years
from entering
clinical
trials, we
probably would
push that
lower down the
list.
Hope that
helps, and
thanks again!
Jason

Hi Jason,

Ahead of your
visit, here
are a few labs
that are doing
innovative
work and may
present
interesting
backgrounds to
become future
stories, or
inform your
reporting. For
antimicrobial
resistance
specifically,
Dr. Fauci is
your best
source. But
the below are
exciting areas
of research at
NIAID, and may
be a fit for
Prognosis. Let
me know if any
of the below
pique your

interest and
we can share
more detail
and/or arrange
time.

- **Skin
microbiome:** NIAID
researchers
developed
[a topical
therapy
for
eczema](#)
that
involves
treating
skin with
"good"
bacteria.
If proven
effective
, this
strategy
could
offer an
inexpensive
treatment
that
requires
less
frequent
application than
many
current
eczema
medications. A
Phase 1/2
trial at
NIH
indicated

that this novel therapy is safe, and most participants experienced improvements in their eczema. NIH has exclusively licensed the technology to Forte Biosciences to advance this potential new therapy through further clinical development.

- **Gene therapy:**
NIAID is developing and applying gene correction techniques to treat a

variety
of
genetic
immune
disorders
. For
example,
NIAID
scientist
s co-
developed
a
lentivira
l gene
therapy
to treat
infants
with X-
SCID, a
rare and
fatal
genetic
immune
deficienc
y. In
clinical
trials,
the gene
therapy
successfu
lly
restored
the
immune
systems
of
infants
newly
diagnosed
with X-
SCID, as
well as
older
children
and young
adults
with the

condition
who
experienc
ed
complex
medical
problems
after
receiving
standard
therapy.
Mustang
Bio is
handling
commercia
l
developme
nt of the
lentivira
l gene
therapy
for X-
SCID.

- **Flu:** Dr.
Jeffrey
Taubenber
ger is a
1918
influenza
expert
who
sequenced
the 1918
pandemic
viral
genome
using
archival
autopsy
specimens
from the
Armed
Forces
Institute
of

Pathology
and
frozen
lung
biopsies
from 1918
flu
victims
interred
in
permafros
t.
Learning
about
1918
pandemic
flu can
help us
better
prepare
for and
target
future
pandemic
strains.
Dr.
Taubenber
ger's lab
is
developin
g a so-
called
universal
flu
vaccine
that
includes
4
inactivat
ed
influenza
viruses
and is
expected
to
undergo
clinical

testing
soon.
Also, Dr.
Matthew
Memoli
leads
NIAID's
influenza
challenge
studies
in which
healthy
volunteer
s are
purposely
exposed
to
influenza
in a
carefully
controlle
d
environme
nt.
Challenge
studies
offer a
unique
opportuni
ty to ask
focused
questions
regarding
influenza
virus
pathogene
sis and
vaccine
efficacy
in a
controlle
d manner.

- **Mosquitoe
s:**
NIAID's

Laborator
y of
Malaria
and
Vector
Research
investiga
tes
disease-
transmitt
ing
insects
and broad
areas of
malaria
biology
and
pathogene
sis. Dr.
Tovi
Lehman
studies
mosquito
ecology,
covering
broad
populatio
n biology
questions
relevant
to
patterns
of
malaria
transmiss
ion and
vector
control.
Recently,
Dr.
Lehman
and
colleague
s in Mali
found
that a
single

mosquito
can
travel up
to 200
miles in
a single
night
with the
right
prevailin
g wind
speed.
The
research
involved
collectin
g flying
insects
using
sticky
nets on
helium-
filled
balloons
suspended
at
varying
heights.

- **Eating
for the
immune
system:**

Dr.
Yasmin
Belkaid
is
researchi
ng
connectio
ns
between
the
microbiom
e,
nutrition

, fat,
and
immunity.
This work
is early
stage,
but
potential
ly
paradigm-
shifting
as she
uncovers
connectio
ns
between
diet and
immunity,
with
implicati
ons for
using
nutrition
to boost
immune
intervent
ions,
including
vaccines.

- **RSV:**
Multiple
researche
rs are
working
to
develop
vaccines
against
respirato
ry
syncytial
virus
(RSV)–
something
most

parents
have
heard of,
but is
not
covered
by media.
RSV
usually
causes
mild
cold-like
symptoms
in
healthy
adults;
however,
RSV can
be
serious,
particula
rly for
infants
and the
elderly.
It is the
most
common
cause of
bronchiol
itis and
pneumonia
in
children
younger
than 1 in
the US.
Scientist
s have
spent
decades
trying to
develop
an
urgently
needed
safe and

effective
vaccine.
One
candidate
known as
DS-Cav1
developed
by [Dr.
Barney
Graham's](#)
team at
NIAID's
Vaccine
Research
Center
has shown
early
promise
in a
[Phase 1
clinical
trial.](#)

I'm CCing my
public affairs
colleagues who
liaise with
these topics
in case there
is follow up.
Looking
forward to
hopefully
meeting you
when you
visit.
Thanks,
Anne

From: Jason
Gale
(BLOOMBERG/
NEWSROOM:)
[<j.gale@bloomberg.net>](mailto:j.gale@bloomberg.net)

Sent:

Thursday,
December 19,
2019 4:24 PM

To: Rancourt,
Anne
(NIH/NIAID)
[E]

(b) (6)

>

Subject:

Re: Following
up on NIH
visit

Hi Anne,

Thanks for
your email and
offer to
assist with
other
interviews.

I'm "old
school," and
see merit in
building
relationships
with
researchers
and hearing
about their
work without
the
expectation of
necessarily
getting a
story.

My interests
are pretty
eclectic --
from
antimicrobial
resistance to

anesthesia. If there's some interesting stuff happening that hasn't been reported on in much detail that speaks to the future of health care (that could be used for our Prognosis platform), I'd be keen to hear about it.

Many thanks again and happy holidays,

Jason

Jason Gale,
HighSec
senior editor
| Bloomberg
News
Level 30, 120
Collins St.,
Melbourne VIC
3000
Tel.
(landline)

(b)(6)

<http://www.linkedin.com/pub/jason-gale/6/249/a56>

From:

(b) (6)

At:

12/20/19

02:54:30

To: Jason Gale
(BLOOMBERG/
NEWSROOM:)

Subject:

Following up
on NIH visit

Hi

Jason,

I

heard
you'll
be

visiti
ng us
at NIH
on

Feb.
28 for

an
interv
iew
with
Dr.

Fauci.
Please
let me
know

if I
can
help
connec

t you
with
other
expert

s
while
you
are

here.
I'd be
happy
to
arrang
e for
you to
see
any
labs
or
hear
from
expert
s on
HIV or
other
diseas
es -
just
let me
know
what
you're
intere
sted
in
hearin
g and
seeing

•
Thanks
!
Lookin
g
forwar
d to
it.

Anne

Anne
Rancou
rt,
MPS
Sectio
n

Chief,
Office
of
Communi-
cations and
Govern-
ment
Relati-
ons
Nation-
al
Instit-
ute of
Allergy and
Infect-
ious
Diseas-
es
Nation-
al
Instit-
utes
of
Health
Pronou-
ns:
She/He
r

(b) (6)

office

(b) (6)

mobile

(b) (6)

Madonna's Secret
for Longevity Seen
Aiding Bacteria
Boom: Health
2012-05-08
21:34:07.963 GMT

By Kanoko
Matsuyama and
Jason Gale
May 9 (Bloomberg)
-- The secret to
Madonna's staying
power
may be surprisingly
simple: gardening.
What the pop star
does involves no
trowel or soil.
Thanks
to dishes of
fermented soy
beans, millet and
brown rice prepared
by her personal
chef, Mayumi
Nishimura,
Madonna practices
a form
of inner horticulture
-- cultivating her
intestinal flora in a
burgeoning
alternative
approach to health.
Studies of the
trillions of bacteria
living on and in the
body suggest the
Material Girl, 53,
may be onto
something. By
eating foods rich in
fiber and laced with
so-called good

bacteria, she may be encouraging helpful microbes to flourish in her bowel, aiding in food digestion and vitamin extraction and possibly staving off diseases from asthma to colon cancer.

“This diet that Madonna is following is very sensible,” says David Topping, chief food-nutrition researcher at Australia’s Commonwealth Scientific and Industrial Research Organization in Adelaide, who studied gut biology for 25 years.

“The bacteria that live inside you are fulfilling very important functions.”

While scientists try to understand the ecology of the bacteria and their interactions with diet and disease, companies are looking for ways to profit.

The health benefits of gut germs have spawned a global market for products

that contain friendly bacteria, called probiotics, in the form of tablets or supplements added to foods by companies including Danone, Nestle SA, and Yakult Honsha Co. The market for supplemented dairy products such as Danone's Activia yoghurts and Yakult's fermented drinks, worth \$14.7 billion six years ago, will probably expand 32 percent to \$33.5 billion by 2016, Euromonitor International estimated last month.

Quinoa, Not Coffee

Studies published in the past year have linked certain bowel-dwelling bacteria to a stronger immune system, while others have been associated with autism and obesity. In one paper published in the journal Nature, scientists showed that a type of white blood

cell that produces antibodies only acquired its infection-fighting ability after spending time in the gut.

Nishimura, who has cooked for cancer patients before being hired by Madonna, serves quinoa and other whole grains as staples, along with vegetables and soy sauce, she said in a telephone interview from New York. She also tries to offer seaweed every second day -- usually sautéed or boiled.

"We eat food processed as little as possible," Nishimura, 55, says of her dietary approach, known as macrobiotic. She doesn't recommend meat, dairy and coffee. An agent for Madonna didn't respond to a request for comment.

Whole grains and fiber act as both food and fertilizer to the bacteria in the bowel, according to Mark Morrison, a

microbiologist with
Australia's CSIRO
in Brisbane
studying ways
to improve gut
function and health.

'Terrific Interest'

There are 10 times
as many bacteria in
the human intestinal
tract as there are
cells in the body. As
coordinator of the
Human Microbiome
Project, Lita Proctor
is helping to
organize
collaboration from
hundreds of
scientists around
the world
trying to map and
study microbial
communities living
on the skin,
in the mouth and
bowel, and in other
parts of the body.
"It's extremely
heartening and
healthy to have so
much
attention now paid
to the diet," says
Proctor, who works
at the
National Human
Genome Institute in
Bethesda,
Maryland.
Even so, Proctor
says the research is
still in its infancy,
and products based

on partial understanding may not deliver what they promise. “That’s not holding up the industry,” she says. “It’s a very fluid, ill-defined area, but with a lot of terrific interest.”

Flowers and Weeds

The term probiotic is vague and there’s no accepted definition for it. Measuring results may be even more of a grey area and some supplements are destroyed by stomach acid before entering the gut, according to Proctor. Nishimura relies on fermented foods such as miso, soy sauce and tempeh to play the role of probiotics and says the benefits of her diet can be quickly noticed. “I feel better than I did 20 years ago,” Madonna wrote in a preface to the cookbook her chef had published in 2010. “I am

very grateful to you for this.”

The garden analogy is helpful when it comes to describing the complex ecology of the bacteria living on humans, says Julie Segre, the lead investigator working on the skin microbiome at the National Human Genome Research Institute.

“There are some flowers that make it easier for other flowers to grow in the same soil,” Segre says. The most important thing is to keep out the invasive weeds, she says.

‘Transpoosions’

When the weeds take over, Australian gastroenterologist Thomas Borody has a radical approach to reestablishing the balance of intestinal flora in his patients: he transplants fecal germs from disease-free individuals directly into the upper reach of the colon, in a pouch

known as the
cecum.
His Sydney clinic
has done 1,800 of
the procedures,
which
he jokingly dubs
“transpoosions,”
over 25 years.
Borody, 62,
says the treatment
has helped patients
with ailments
ranging
from autism to
pseudomembranou
s colitis, a resilient
infection
that causes
abdominal pain,
loose bowel
movements and
fever.
“The next day their
diarrhea stops,” the
doctor says.
After the procedure,
he asks patients to
avoid treatments
that
may damage their
gut flora. Three
studies presented
at the
American College
of
Gastroenterology’s
meeting in October
indicate fecal
transplants can help
with bouts of
diarrhea
associated with the
bacterium
Clostridium difficile.

When Weeds Take Over

Keeping inner bugs healthy is crucial because otherwise they risk taking over more than the garden. If intestinal bacteria aren't able to survive on the food their host consumes, the germs will try to feed on what they can find -- "mucus as well as anything else," according to CSIRO's Topping. That may lead to inflammatory bowel disease, a painful condition that can evolve into colon cancer, he says. Staving off disease is one reason people have turned to Nishimura's cooking in the past. The chef, who prepared meals for cancer patients in Boston, says the diet helps with constipation, menstrual pain and body odor. When she first changed the way she ate, Nishimura says she also found that her

allergic skin rash improved.

'So Fresh'

Typically, Nishimura tailors her meals each day to suit the way her employer feels, she says, adding that Madonna prefers the chef herself to shop for ingredients. Popular dishes include seaweed in miso soup; hijiki -- a type of brown seaweed -

- served with carrots and onions and seasoned with soy sauce; and cooked oats for breakfast, Nishimura says. Whole grains demand harder work for bowel bacteria, which help the body extract vitamins and nutrients from food, because the insoluble fiber they contain is only broken down in the lower reaches of the digestive tract in a fermentation process that delivers different quantities and varieties of inflammation-

fighting short-chain fatty acids to the body's cells.

There is "solid evidence" that microbes play a role in

tuning the immune system, says Ian Lipkin, director of the

Center for Infection and Immunity at Columbia

University's Mailman School of Public Health,

where scientists showed in

January that

children with autism and gastrointestinal disturbances have a bacterial species

not found in non-autistic

children with tummy upsets.

Madonna and others making similar diet choices may not know

they're pushing the science frontier.

They may just feel better.

"When you cut out animal products, white sugar and coffee

for 10 days you start to feel the difference,"

Nishimura said.

"When I first began

this diet, I
remember how my
head became
clearer, I woke up
earlier and felt so
fresh in the morning
that
I didn't want to stay
in bed.”
Madonna herself
isn't lacking in
stamina. Her world
tour,
which starts in Tel
Aviv this month and
ends next March,
includes 75
concerts in Europe
and North America.
Her previous
world tour was in
2008 and 2009,
when she also
published six
children's books
and directed or
produced two
movies.

For Related News
and Information:
Most-read health-
care stories: MNI
HEA <GO>
Bloomberg's top
health stories:
HTOP <GO>
Bloomberg's top
stories on Japan:
TOPY <GO>
Bloomberg drug
database: BDRG
<GO>

--Editors: Marthe
Fourcade, Rick

Schine.

To contact the
reporters
responsible for this
story:

Kanoko Matsuyama
in Tokyo at +81-3-
3201-3490 or
[kmatsuyama2@blo
omberg.net](mailto:kmatsuyama2@bloomberg.net);

Jason Gale in
Melbourne at (b) (6)

or
[j.gale@bloomberg.n
et](mailto:j.gale@bloomberg.net)

To contact the
editor responsible
for this story:

Jason Gale at +65-
6212-1579 or

[j.gale@bloomberg.n
et](mailto:j.gale@bloomberg.net).